CD8A and melanoma: We then evaluated whether the r3LCMV treatment improves tumor-specific T cell responses, by challenging mice with B16 melanoma cells expressing ovalbumin (B16-OVA) and then measuring OVA-specific CD8+ T cell responses by KbSIINFEKL tetramer staining.